Prothena | PRTA - 股本和储备



金融业
股票价格
USD
资产
USD 349.89M
现金及等价物
USD 329.46M
销售成本
USD 28.94M
流动资产
USD 339.2M
流动负债
USD 32.52M
债务
USD 7.65M
EBIT
USD 25.79M
EBITDA
USD 25.98M
员工
163
EPS每股收益
USD 0.6
股本和储备
USD 312.62M
销售毛利
USD 51.08M
债务利息支出
USD 349.89M
利息收入
USD 2.42M
贷款资金
USD 0
市值
USD 520.6M
净收入
USD 32.72M
营业费用
USD 25.29M
营业利润
USD 25.79M
普通股股本
USD 53.08M
PE价格收益
22.11
税前利润
USD 32.72M
销售收入
USD 51.08M
销售和管理费用
USD 12.67M
贸易债权人
USD 4.3M
应收帐款人
USD 5.16M


股本和储备 更改 日
Acadia Pharmaceuticals USD 1.25B 20.68M 2026-03
Agios Pharmaceuticals USD 1.11B 84M 2026-03
Akebia Therapeutics USD 27.38M 5.24M 2026-03
ALKERMES USD 1.75B 67.76M 2026-03
Alnylam Pharmaceuticals USD 1.08B 286.2M 2026-03
Amgen USD 9.19B 532M 2026-03
Biogen USD 18.65B 394.9M 2026-03
BioMarin Pharmaceutical USD 6.21B 125.11M 2026-03
Exelixis USD 1.94B 225.57M 2026-03
Immunic USD 151.23M 157.91M 2026-03
Incyte USD 5.62B 455.37M 2026-03
Ionis Pharmaceuticals USD 491.41M 2.32M 2026-03
MacroGenics USD 21.2M 34.39M 2026-03
Nektar Therapeutics USD 89.83M 4.75M 2025-12
Neurocrine Biosciences USD 3.41B 154.3M 2026-03
Prothena USD 312.62M 32.14M 2026-03
Regeneron Pharmaceuticals USD 31.42B 166.7M 2026-03
Ultragenyx Pharmaceutical USD -236M 156M 2026-03
Vertex Pharmaceuticals USD 19.36B 696.1M 2026-03
Xoma USD 87.94M 15.5M 2025-09